Clinical features of de novo CD25⁺ diffuse large B-cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–5.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Lowenthal JW, Zubler RH, Nabholz M, MacDonald HR. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature. 1985;315:669–72.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5–8.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007;26:3699–703.
   PubMed Web of Science ®Google Scholar
• Tesch H, Günther A, Abts H, Jücker M, Klein S, Krueger GR, et al. Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol. 1993;142:1714–20.
   PubMed Web of Science ®Google Scholar
• Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, et al. A Phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res. 2009;15:7701–10.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, et al. Phase II study on combination therapy with CHOP-Zenapax or HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leuk Res. 2012;36:857–61.
   PubMed Web of Science ®Google Scholar
• de Totero D, Francia di Celle P, Cignetti A, Foa R. The IL-2 receptor complex: expression and function on normal and leukemic B cells. Leukemia. 1995;9:1425–31.
   PubMed Web of Science ®Google Scholar
• Tsilivakos V, Tsapis A, Kakolyris S, Iliakis P, Perraki M, Georgoulias V. Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia. 1994;8:1571–8.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91:705–14.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol. 2009;20:526–33.
   PubMed Web of Science ®Google Scholar
• Morito T, Fujihara M, Asaoku H, Tari A, Sato Y, Ichimura K, et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci. 2009;100:1255–60.
   PubMed Web of Science ®Google Scholar
• Oka S, Nagatsuka Y, Kikuchi J, Yokote T, Hirabayashi Y, Hanafusa T, et al. Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway. Leuk Lymphoma. 2009;50:1190–7.
   PubMed Web of Science ®Google Scholar
• Oka S, Muroi K, Matsuyama T, Sato K, Ueda M, Toshima M, et al. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia. Hematology. 2009;14:133–8.
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665–74.
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209–39.
   PubMed Web of Science ®Google Scholar
• Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases a review. Med Sci Monit. 2008;14:RA179–89.
   PubMed Web of Science ®Google Scholar
• Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Strömberg U, Loskog AS. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology. 2010;131:371–6.
   PubMed Web of Science ®Google Scholar
• Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. Immunology. 2006;117:548–57.
   PubMed Web of Science ®Google Scholar
• Amu S, Tarkowski A, Dörner T, Bokarewa M, Brisslert M, Scand J. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Immunology. 2007;66:77–86.
   Web of Science ®Google Scholar
• Kube D, Vockerodt M, Weber O, Hell K, Wolf J, Haier B, et al. Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol. 1999;73:1630–6.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16:87–96.
   PubMed Web of Science ®Google Scholar